| Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 … FM Blows, KE Driver, MK Schmidt, A Broeks, FE Van Leeuwen, ... PLoS medicine 7 (5), e1000279, 2010 | 1367 | 2010 |
| Reversible and adaptive resistance to BRAF (V600E) inhibition in melanoma C Sun, L Wang, S Huang, GJJE Heynen, A Prahallad, C Robert, ... Nature 508 (7494), 118-122, 2014 | 991 | 2014 |
| Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Wesseling, SW van der Valk, HL Vos, A Sonnenberg, J Hilkens The Journal of cell biology 129 (1), 255-265, 1995 | 551 | 1995 |
| Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure M Donker, ME Straver, J Wesseling, CE Loo, M Schot, CA Drukker, ... Annals of surgery 261 (2), 378-382, 2015 | 522 | 2015 |
| A mechanism for inhibition of E-cadherin-mediated cell-cell adhesion by the membrane-associated mucin episialin/MUC1. J Wesseling, SW van der Valk, J Hilkens Molecular biology of the cell 7 (4), 565-577, 1996 | 483 | 1996 |
| Personalized early detection and prevention of breast cancer: ENVISION consensus statement N Pashayan, AC Antoniou, U Ivanus, LJ Esserman, DF Easton, D French, ... Nature reviews Clinical oncology 17 (11), 687-705, 2020 | 480 | 2020 |
| Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer RL Milne, KB Kuchenbaecker, K Michailidou, J Beesley, S Kar, ... Nature genetics 49 (12), 1767-1778, 2017 | 474 | 2017 |
| Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients C Yau, M Osdoit, M van der Noordaa, S Shad, J Wei, D de Croze, ... The Lancet Oncology 23 (1), 149-160, 2022 | 473 | 2022 |
| Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised … MS van Ramshorst, A van der Voort, ED van Werkhoven, IA Mandjes, ... The Lancet Oncology 19 (12), 1630-1640, 2018 | 437 | 2018 |
| Feasibility of a prospective, randomised, open-label, international multicentre, phase III, non-inferiority trial to assess the safety of active surveillance for low risk … LE Elshof, K Tryfonidis, L Slaets, AE van Leeuwen-Stok, VP Skinner, N Dif, ... European journal of cancer 51 (12), 1497-1510, 2015 | 420 | 2015 |
| Ductal carcinoma in situ: to treat or not to treat, that is the question M van Seijen, EH Lips, AM Thompson, S Nik-Zainal, A Futreal, ES Hwang, ... British journal of cancer 121 (4), 285-292, 2019 | 418 | 2019 |
| Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy M Jalving, JJ Koornstra, J Wesseling, HM Boezen, S De Jong, ... Alimentary pharmacology & therapeutics 24 (9), 1341-1348, 2006 | 396 | 2006 |
| Somatic mutations in the chromatin remodeling gene ARID1A occur in several tumor types S Jones, M Li, DW Parsons, X Zhang, J Wesseling, P Kristel, MK Schmidt, ... Human mutation 33 (1), 100-103, 2012 | 371 | 2012 |
| Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype CE Loo, ME Straver, S Rodenhuis, SH Muller, J Wesseling, ... Journal of Clinical Oncology 29 (6), 660-666, 2011 | 359 | 2011 |
| The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer ME Straver, AM Glas, J Hannemann, J Wesseling, MJ van de Vijver, ... Breast cancer research and treatment 119 (3), 551-558, 2010 | 351 | 2010 |
| Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) JM Bueno-de-Mesquita, WH van Harten, VP Retel, LJ van't Veer, ... The lancet oncology 8 (12), 1079-1087, 2007 | 351 | 2007 |
| A prospective evaluation of a breast cancer prognosis signature in the observational RASTER study CA Drukker, JM Bueno‐de‐Mesquita, VP Retèl, WH van Harten, ... International journal of cancer 133 (4), 929-936, 2013 | 318 | 2013 |
| Tissue distribution of the death ligand TRAIL and its receptors DC Spierings, EG de Vries, E Vellenga, FA van den Heuvel, JJ Koornstra, ... Journal of Histochemistry & Cytochemistry 52 (6), 821-831, 2004 | 307 | 2004 |
| Tumour-specific proline vulnerability uncovered by differential ribosome codon reading F Loayza-Puch, K Rooijers, LCM Buil, J Zijlstra, J F. Oude Vrielink, ... Nature 530 (7591), 490-494, 2016 | 303 | 2016 |
| Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers EH Lips, L Mulder, A Oonk, LE Van Der Kolk, FBL Hogervorst, ALT Imholz, ... British journal of cancer 108 (10), 2172-2177, 2013 | 301 | 2013 |
E Rutgershoogleraar chirurgische oncologie UvAVerified email at nki.nl
